Kristian Thorlund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristian Thorlund has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Edward J. Mills
Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada
10 shared publications Louis Dron
MTEK Sciences, Vancouver, BC, V5Z 1J5, Canada
8 shared publicationsEllie Siden
MTEK Sciences, Vancouver, BC, V5Z 1J5, Canada
6 shared publicationsJay J. H. Park
MTEK Sciences, Vancouver, BC, V5Z 1J5, Canada
6 shared publicationsNoor-E Zannat
MTEK Sciences, Vancouver, BC, V5Z 1J5, Canada
6 shared publicationsOfir Harari
MTEK Sciences, Vancouver, BC, V5Z 1J5, Canada
6 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in BMC Medical Research Methodology
Adaptive platform trials: A revolution or a fleeting trend? A review of the strengths and limitations
Platform trials have gained significant attention in recent years, particularly during the COVID-19 pandemic, for their potential to deliver efficient and flexible clinical research. Designed to evaluate multiple interventions within a single, ongoing infrastructure, platform trials allow for dynamic trial modifications, such as adding or removing treatment arms. These features offer potential advantages over conventional randomised controlled trials, including resource optimisation, reduced participant numbers, and faster evaluation of new therapies. Despite these potential strengths, the design and implementation of platform trials are associated with several methodological and logistical challenges that may undermine their validity. This review critically evaluates the platform trial methodology, exploring its potential to revolutionise clinical research or serve merely as a transient innovation. We discuss key advantages such as infrastructure reusability, cost-effectiveness, and efficiency in comparative effectiveness research. However, we also highlight significant limitations. These include a frequent lack of blinding, reliance on non-concurrent control groups, and the use of response-adaptive randomisation, all of which may introduce bias, reduce statistical power, and compromise internal validity. Additional issues such as increased ethical and regulatory complexity, underreporting of negative results, and insufficient realisation of theoretical efficiencies further temper the enthusiasm for this design. Evidence from recent systematic reviews reveals that many platform trials do not fully exploit their potential—40% have not added new arms, and only a minority conduct appropriate statistical adjustments for multiple testing. Nevertheless, simulations suggest long-term cost and time savings compared to traditional randomised controlled trials, assuming adequate implementation. We conclude that platform trials are not inherently flawed, although must be designed and conducted with rigorous methodological standards. Their success depends on maintaining core principles of trial integrity—especially reducing the risks of systematic, random, and design errors—while navigating operational and regulatory challenges. Platform trials are likely to become an integral part of the clinical trial landscape, provided they supplement, rather than compromise, the foundations of evidence-based medicine.
- 21 October 2026
- Published by Springer Nature in BMC Medical Research Methodology
Open AccessAdaptive platform trials: A revolution or a fleeting trend? A review of the strengths and limitations
Platform trials have gained significant attention in recent years, particularly during the COVID-19 pandemic, for their potential to deliver efficient and flexible clinical research. Designed to evaluate multiple interventions within a single, ongoing infrastructure, platform trials allow for dynamic trial modifications, such as adding or removing treatment arms. These features offer potential advantages over conventional randomised controlled trials, including resource optimisation, reduced participant numbers, and faster evaluation of new therapies. Despite these potential strengths, the design and implementation of platform trials are associated with several methodological and logistical challenges that may undermine their validity. This review critically evaluates the platform trial methodology, exploring its potential to revolutionise clinical research or serve merely as a transient innovation. We discuss key advantages such as infrastructure reusability, cost-effectiveness, and efficiency in comparative effectiveness research. However, we also highlight significant limitations. These include a frequent lack of blinding, reliance on non-concurrent control groups, and the use of response-adaptive randomisation, all of which may introduce bias, reduce statistical power, and compromise internal validity. Additional issues such as increased ethical and regulatory complexity, underreporting of negative results, and insufficient realisation of theoretical efficiencies further temper the enthusiasm for this design. Evidence from recent systematic reviews reveals that many platform trials do not fully exploit their potential—40% have not added new arms, and only a minority conduct appropriate statistical adjustments for multiple testing. Nevertheless, simulations suggest long-term cost and time savings compared to traditional randomised controlled trials, assuming adequate implementation. We conclude that platform trials are not inherently flawed, although must be designed and conducted with rigorous methodological standards. Their success depends on maintaining core principles of trial integrity—especially reducing the risks of systematic, random, and design errors—while navigating operational and regulatory challenges. Platform trials are likely to become an integral part of the clinical trial landscape, provided they supplement, rather than compromise, the foundations of evidence-based medicine.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-10
Logistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency
Platform randomized trials offer a flexible framework for evaluating multiple therapies within a shared long-term infrastructure, yet their implementation poses substantial logistical and operational challenges. This paper examines three interrelated features that frequently determine the feasibility and efficiency of platform trials: 1) infrastructure and setup costs; 2) training, site management, and partial center participation; and 3) adapting to changing clinical practice and diagnostic criteria. While platform designs are often promoted for their efficiency, the establishment and maintenance of long-term infrastructure require greater upfront investment, more complex governance structures, and ongoing retraining compared to conventional randomized trials. Site heterogeneity and partial participation can create inconsistencies in implementation, data quality, and recruitment momentum. Over the long term, evolving standards of care and diagnostic definitions further complicate cross-arm comparability and risk introducing time-confounding. Rather than assuming platform trials are inherently more efficient, we argue that their success depends on sustained resourcing, harmonization efforts, sustained dedication from trial sites, and a robust training infrastructure. To address these challenges, we describe a trial-to-platform approach: a phased strategy in which a conventional multicenter trial is launched with modular, expandable systems that can later evolve to a platform trial. This approach allows for early learning, milestone-based funding, harmonization before full expansion, thereby reducing cost inefficiency and operational drift. Practical recommendations are provided for funders and trialists on how to structure, resource, and govern platforms to ensure scalability, reproducibility, and long-term sustainability.
- 1 May 2026
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 18, 1-10
Open AccessLogistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency
Platform randomized trials offer a flexible framework for evaluating multiple therapies within a shared long-term infrastructure, yet their implementation poses substantial logistical and operational challenges. This paper examines three interrelated features that frequently determine the feasibility and efficiency of platform trials: 1) infrastructure and setup costs; 2) training, site management, and partial center participation; and 3) adapting to changing clinical practice and diagnostic criteria. While platform designs are often promoted for their efficiency, the establishment and maintenance of long-term infrastructure require greater upfront investment, more complex governance structures, and ongoing retraining compared to conventional randomized trials. Site heterogeneity and partial participation can create inconsistencies in implementation, data quality, and recruitment momentum. Over the long term, evolving standards of care and diagnostic definitions further complicate cross-arm comparability and risk introducing time-confounding. Rather than assuming platform trials are inherently more efficient, we argue that their success depends on sustained resourcing, harmonization efforts, sustained dedication from trial sites, and a robust training infrastructure. To address these challenges, we describe a trial-to-platform approach: a phased strategy in which a conventional multicenter trial is launched with modular, expandable systems that can later evolve to a platform trial. This approach allows for early learning, milestone-based funding, harmonization before full expansion, thereby reducing cost inefficiency and operational drift. Practical recommendations are provided for funders and trialists on how to structure, resource, and govern platforms to ensure scalability, reproducibility, and long-term sustainability.
- Open Access
- 18 December 2025
- Published by Springer Nature in Trials
- Vol. 27 (1)
Treatment guided by cerebral oximetry in mechanically ventilated newborns: a statistical analysis plan for step one of the SafeBoosC-IIIv randomised clinical trial
Newborns requiring invasive mechanical ventilation are at high risk of neurodevelopmental impairment, prolonged hospitalisation, and increased mortality. T
- 18 December 2025
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessTreatment guided by cerebral oximetry in mechanically ventilated newborns: a statistical analysis plan for step one of the SafeBoosC-IIIv randomised clinical trial
Newborns requiring invasive mechanical ventilation are at high risk of neurodevelopmental impairment, prolonged hospitalisation, and increased mortality. T
- Open Access
- 1 March 2024
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 13 (3) , e230147
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers
Development of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-world data is typically fraught with limitations including missing data, measurement error and the potential for unmeasured confounding given a nonrandomized comparison. Quantitative bias analysis (QBA) comprises a collection of approaches for modelling the magnitude of systematic errors in data which cannot be addressed with conventional statistical adjustment. Their applications can range from simple deterministic equations to complex hierarchical models. QBA applied to external control arm represent an opportunity for evaluating the validity of the corresponding comparative efficacy estimates. We provide a brief overview of available QBA approaches and explore their application in practice. Using a motivating example of a comparison between pralsetinib single-arm trial data versus pembrolizumab alone or combined with chemotherapy real-world data for RET fusion-positive advanced non-small cell lung cancer (aNSCLC) patients (1–2% among all NSCLC), we illustrate how QBA can be applied to external control arms. We illustrate how QBA is used to ascertain robustness of results despite a large proportion of missing data on baseline ECOG performance status and suspicion of unknown confounding. The robustness of findings is illustrated by showing that no meaningful change to the comparative effect was observed across several ‘tipping-point’ scenario analyses, and by showing that suspicion of unknown confounding was ruled out by use of E-values. Full R code is also provided.
- 1 March 2024
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 13 (3) , e230147
Open AccessQuantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers
Development of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-world data is typically fraught with limitations including missing data, measurement error and the potential for unmeasured confounding given a nonrandomized comparison. Quantitative bias analysis (QBA) comprises a collection of approaches for modelling the magnitude of systematic errors in data which cannot be addressed with conventional statistical adjustment. Their applications can range from simple deterministic equations to complex hierarchical models. QBA applied to external control arm represent an opportunity for evaluating the validity of the corresponding comparative efficacy estimates. We provide a brief overview of available QBA approaches and explore their application in practice. Using a motivating example of a comparison between pralsetinib single-arm trial data versus pembrolizumab alone or combined with chemotherapy real-world data for RET fusion-positive advanced non-small cell lung cancer (aNSCLC) patients (1–2% among all NSCLC), we illustrate how QBA can be applied to external control arms. We illustrate how QBA is used to ascertain robustness of results despite a large proportion of missing data on baseline ECOG performance status and suspicion of unknown confounding. The robustness of findings is illustrated by showing that no meaningful change to the comparative effect was observed across several ‘tipping-point’ scenario analyses, and by showing that suspicion of unknown confounding was ruled out by use of E-values. Full R code is also provided.
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S279
MSR8 Update on the LIVESTARTTM Artificial Intelligence (AI) Systematic Literature Review (SLR) Tool – Can It Aid in Limited Data Extraction for LIVEREFTM?
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S279
MSR8 Update on the LIVESTARTTM Artificial Intelligence (AI) Systematic Literature Review (SLR) Tool – Can It Aid in Limited Data Extraction for LIVEREFTM?
- 19 October 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (1) , 49-60
Infliximab as a second‐line therapy for children with refractory Kawasaki disease: A systematic review and meta‐analysis of randomized controlled trials
Aims: Infliximab is a tumour necrosis factor‐alpha inhibitor that is used to treat children with refractory Kawasaki disease (KD). Our purpose was to evaluate the safety and impact of infliximab versus intravenous immunoglobulins on the incidence of coronary artery aneurysms (CAAs) and treatment resistance in children with refractory KD.Methods: The Medline/PubMed, Embase, CINAHL, Cochrane Central Register of Controlled Trials and clinical trials registries were searched to December 2021. Randomized controlled trials (RCTs) comparing infliximab as second‐line therapy to a second dose of intravenous immunoglobulin (IVIG) in children with refractory KD, reported in abstract or full text, were included. Studies were selected and assessed for risk of bias by two reviewers. Data were extracted and pooled using conventional random‐effects meta‐analysis. The certainty of evidence was assessed using the GRADE system.Results: A total of 199 participants from four RCTs were included. The pooled risk ratio (RR) for the incidence of treatment resistance in patients treated with infliximab was 0.40 (95% confidence interval [CI] 0.25‐0.64). For incidence of CAAs RR was 1.20 (95% CI 0.54‐2.63), the incidence of adverse effect “infusion reactions” RR was 0.48, (95% CI 0.12‐1.92) and for “infections” RR was 0.55 (95% CI 0.27‐1.12). Overall, the GRADE strength of evidence for the primary outcomes was low. Evidence on the duration of fever and inflammatory biomarkers was sparse, heterogeneous and inconclusive.Conclusion: Moderate‐certainty evidence indicates that infliximab may reduce the incidence of treatment resistance in children with refractory KD. However, the limited strength of evidence warrants further research.
- 19 October 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (1) , 49-60
Infliximab as a second‐line therapy for children with refractory Kawasaki disease: A systematic review and meta‐analysis of randomized controlled trials
Aims: Infliximab is a tumour necrosis factor‐alpha inhibitor that is used to treat children with refractory Kawasaki disease (KD). Our purpose was to evaluate the safety and impact of infliximab versus intravenous immunoglobulins on the incidence of coronary artery aneurysms (CAAs) and treatment resistance in children with refractory KD.Methods: The Medline/PubMed, Embase, CINAHL, Cochrane Central Register of Controlled Trials and clinical trials registries were searched to December 2021. Randomized controlled trials (RCTs) comparing infliximab as second‐line therapy to a second dose of intravenous immunoglobulin (IVIG) in children with refractory KD, reported in abstract or full text, were included. Studies were selected and assessed for risk of bias by two reviewers. Data were extracted and pooled using conventional random‐effects meta‐analysis. The certainty of evidence was assessed using the GRADE system.Results: A total of 199 participants from four RCTs were included. The pooled risk ratio (RR) for the incidence of treatment resistance in patients treated with infliximab was 0.40 (95% confidence interval [CI] 0.25‐0.64). For incidence of CAAs RR was 1.20 (95% CI 0.54‐2.63), the incidence of adverse effect “infusion reactions” RR was 0.48, (95% CI 0.12‐1.92) and for “infections” RR was 0.55 (95% CI 0.27‐1.12). Overall, the GRADE strength of evidence for the primary outcomes was low. Evidence on the duration of fever and inflammatory biomarkers was sparse, heterogeneous and inconclusive.Conclusion: Moderate‐certainty evidence indicates that infliximab may reduce the incidence of treatment resistance in children with refractory KD. However, the limited strength of evidence warrants further research.
- 10 September 2022
- Published by SAGE Publications in Clinical Trials
- Vol. 19 (6) , 613-622
A Bayesian adaptive design for clinical trials of rare efficacy outcomes with multiple definitions
Introduction: Bayesian adaptive designs for clinical trials have gained popularity in the recent years due to the flexibility and efficiency that they offer. We consider the scenario where the outcome of interest comprises events with relatively low risk of occurrence and different case definitions resulting in varying control group risk assumptions. This is a scenario that occurs frequently for infectious diseases in global health research. Methods: We propose a Bayesian adaptive design that incorporates different case definitions of the outcome of interest that vary in stringency. A set of stopping rules are proposed where superiority and futility may be concluded with respect to different outcome definitions and therefore maintain a realistic probability of stopping in trials with low event rates. Through a simulation study, a variety of stopping rules and design configurations are compared. Results: The simulation results are provided in an interactive web application that allows the user to explore and compare the design operating characteristics for a variety of assumptions and design parameters with respect to different outcome definitions. The results for select simulation scenarios are provided in the article. Discussion: Bayesian adaptive designs offer the potential for maximizing the information learned from the data collected through clinical trials. The proposed design enables monitoring and utilizing multiple composite outcomes based on rare events to optimize the trial design operating characteristics.
- 10 September 2022
- Published by SAGE Publications in Clinical Trials
- Vol. 19 (6) , 613-622
A Bayesian adaptive design for clinical trials of rare efficacy outcomes with multiple definitions
Introduction: Bayesian adaptive designs for clinical trials have gained popularity in the recent years due to the flexibility and efficiency that they offer. We consider the scenario where the outcome of interest comprises events with relatively low risk of occurrence and different case definitions resulting in varying control group risk assumptions. This is a scenario that occurs frequently for infectious diseases in global health research. Methods: We propose a Bayesian adaptive design that incorporates different case definitions of the outcome of interest that vary in stringency. A set of stopping rules are proposed where superiority and futility may be concluded with respect to different outcome definitions and therefore maintain a realistic probability of stopping in trials with low event rates. Through a simulation study, a variety of stopping rules and design configurations are compared. Results: The simulation results are provided in an interactive web application that allows the user to explore and compare the design operating characteristics for a variety of assumptions and design parameters with respect to different outcome definitions. The results for select simulation scenarios are provided in the article. Discussion: Bayesian adaptive designs offer the potential for maximizing the information learned from the data collected through clinical trials. The proposed design enables monitoring and utilizing multiple composite outcomes based on rare events to optimize the trial design operating characteristics.
- Open Access
- 11 March 2022
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 106 (5) , 1301-1304
Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
: Oral therapies for the early treatment of COVID-19 may prevent disease progression and health system overcrowding. A new oral therapeutic named molnupiravir has been promoted as providing an approximately 50% reduction in death or the need for hospitalization. The clinical trial evaluating this drug was stopped early at the recommendation of the Data Safety and Monitoring Board after approximately 50% of the sample had been recruited. At the point of discontinuing the trial, approximately 90% of the planned sample had been recruited and had available follow-up data accessible. We discuss issues about the study conduct, analysis, and interpretation, including 1) the authors and sponsors presented the interim analysis as the primary analysis; 2) communication between sponsors and the Data Safety and Monitoring Board was insufficient; 3) the treatment effects reverse when examining only the post-interim analysis population, and are substantially attenuated when examining the full data; 4) the choice of primary analysis is incorrect; 5) analysis of lost-to-follow-up patients favors the study drug; and 6) other known molnupiravir trials were not presented in the primary study findings. As a result of methodological and statistical concerns, it seems that external trials, separate from those supported by the sponsoring company, are required to determine the utility of this drug.
- 11 March 2022
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 106 (5) , 1301-1304
Open AccessMaking Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
: Oral therapies for the early treatment of COVID-19 may prevent disease progression and health system overcrowding. A new oral therapeutic named molnupiravir has been promoted as providing an approximately 50% reduction in death or the need for hospitalization. The clinical trial evaluating this drug was stopped early at the recommendation of the Data Safety and Monitoring Board after approximately 50% of the sample had been recruited. At the point of discontinuing the trial, approximately 90% of the planned sample had been recruited and had available follow-up data accessible. We discuss issues about the study conduct, analysis, and interpretation, including 1) the authors and sponsors presented the interim analysis as the primary analysis; 2) communication between sponsors and the Data Safety and Monitoring Board was insufficient; 3) the treatment effects reverse when examining only the post-interim analysis population, and are substantially attenuated when examining the full data; 4) the choice of primary analysis is incorrect; 5) analysis of lost-to-follow-up patients favors the study drug; and 6) other known molnupiravir trials were not presented in the primary study findings. As a result of methodological and statistical concerns, it seems that external trials, separate from those supported by the sponsoring company, are required to determine the utility of this drug.
- Open Access
- 1 September 2021
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 137, 265
Corrigendum to GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011;64:1283–1293
- 1 September 2021
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 137, 265
Open AccessCorrigendum to GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011;64:1283–1293
- Open Access
- 24 September 2020
- Published by F1000 Research Ltd in Gates Open Research
- Vol. 3, 1720
Interventions to improve linear growth during exclusive breastfeeding life-stage for children aged 0-6 months living in low- and middle-income countries: a systematic review with network and pairwise meta-analyses
Background:Exclusive breastfeeding (EBF) during the first six months of life is critical for child’s linear growth. While there is strong evidence in favor of EBF, the evidence with regards to other interventions for linear growth is unclear. We evaluated intervention domains of micronutrients, food supplements, deworming, maternal education, water sanitation and hygiene (WASH), and kangaroo care, for their comparative effectiveness on linear growth. Methods:For this review, we searched for randomized clinical trials (RCTs) of the interventions provided to infants aged 0-6 months and/or their breastfeeding mothers in low- and middle-income countries reporting on length-for-age z-score (LAZ), stunting, length, and head circumference. We searched for reports published until September 17th, 2019 and hand-searched bibliographies of existing reviews. For LAZ and stunting, we used network meta-analysis (NMA) to compare the effects of all interventions except for kangaroo care, where we used pairwise meta-analysis to compare its effects versus standard-of-care. For length and head circumference, we qualitatively summarized our findings. Results:We found 29 RCTs (40 papers) involving 35,119 mother and infant pairs reporting on the effects of aforementioned interventions on linear growth outcomes. Our NMA on LAZ found that compared to standard-of-care, multiple micronutrients administered to infants (MMN-C) improved LAZ (mean difference: 0.20; 95% credible interval [CrI]: 0.03,0.35), whereas supplementing breastfeeding mothers with MMN did not (MMN-M, mean difference: -0.02, 95%CrI: -0.18,0.13). No interventions including MMN-C (relative risk: 0.74; 95%CrI: 0.36,1.44) reduced risk for stunting compared to standard-of-care. Kangaroo care, on the other hand, improved head circumference (mean difference: 0.20 cm/week; 95% confidence intervals [CI]: 0.09,0.31 cm/week) and length (mean difference: 0.23 cm/week; 95%CI: 0.10,0.35 cm/week) compared to standard-of-care. Conclusion:Our study found important improvements for kangaroo care, but we did not find sufficient evidence for other interventions. Registration:PROSPEROCRD42018110450; registered on 17 October 2018.
- 24 September 2020
- Published by F1000 Research Ltd in Gates Open Research
- Vol. 3, 1720
Open AccessInterventions to improve linear growth during exclusive breastfeeding life-stage for children aged 0-6 months living in low- and middle-income countries: a systematic review with network and pairwise meta-analyses
Background:Exclusive breastfeeding (EBF) during the first six months of life is critical for child’s linear growth. While there is strong evidence in favor of EBF, the evidence with regards to other interventions for linear growth is unclear. We evaluated intervention domains of micronutrients, food supplements, deworming, maternal education, water sanitation and hygiene (WASH), and kangaroo care, for their comparative effectiveness on linear growth. Methods:For this review, we searched for randomized clinical trials (RCTs) of the interventions provided to infants aged 0-6 months and/or their breastfeeding mothers in low- and middle-income countries reporting on length-for-age z-score (LAZ), stunting, length, and head circumference. We searched for reports published until September 17th, 2019 and hand-searched bibliographies of existing reviews. For LAZ and stunting, we used network meta-analysis (NMA) to compare the effects of all interventions except for kangaroo care, where we used pairwise meta-analysis to compare its effects versus standard-of-care. For length and head circumference, we qualitatively summarized our findings. Results:We found 29 RCTs (40 papers) involving 35,119 mother and infant pairs reporting on the effects of aforementioned interventions on linear growth outcomes. Our NMA on LAZ found that compared to standard-of-care, multiple micronutrients administered to infants (MMN-C) improved LAZ (mean difference: 0.20; 95% credible interval [CrI]: 0.03,0.35), whereas supplementing breastfeeding mothers with MMN did not (MMN-M, mean difference: -0.02, 95%CrI: -0.18,0.13). No interventions including MMN-C (relative risk: 0.74; 95%CrI: 0.36,1.44) reduced risk for stunting compared to standard-of-care. Kangaroo care, on the other hand, improved head circumference (mean difference: 0.20 cm/week; 95% confidence intervals [CI]: 0.09,0.31 cm/week) and length (mean difference: 0.23 cm/week; 95%CI: 0.10,0.35 cm/week) compared to standard-of-care. Conclusion:Our study found important improvements for kangaroo care, but we did not find sufficient evidence for other interventions. Registration:PROSPEROCRD42018110450; registered on 17 October 2018.